One-Shot gene therapy could replace monthly eye injections for vision loss
NCT ID NCT06825858
Summary
This is an early-stage safety study testing a new gene therapy called KH658 for people with 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. The therapy is designed as a one-time injection into the eye to deliver a gene that helps block the abnormal blood vessel growth that damages vision. The main goal is to see if this single treatment is safe and tolerable, with the hope it could reduce the need for the frequent anti-VEGF injections that are the current standard of care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanghong Investigative Site
Phoenix, Arizona, 85016, United States
-
Kanghong Investigative Site
Lemont, Illinois, 60439, United States
-
Kanghong Investigative Site
Memphis, Tennessee, 38138, United States
Conditions
Explore the condition pages connected to this study.